Literature DB >> 18452050

Increase of osteopontin plasma concentrations after bariatric surgery independent from inflammation and insulin resistance.

Georg Schaller1, Yoshimasa Aso, Gerit-Holger Schernthaner, Hans-Peter Kopp, Toshihiko Inukai, Stefan Kriwanek, Guntram Schernthaner.   

Abstract

BACKGROUND: Osteopontin (OPN) is a multifunctional matrix glycoprotein associated with bone metabolism and has been linked to chronic inflammation, insulin resistance, and atherosclerosis. Diet-induced weight loss decreases elevated OPN concentrations in obese patients. The aim of the current study was to investigate the role of OPN after bariatric surgery, where not only improvements of chronic inflammation, insulin resistance and comorbidities, but also malabsorption and altered bone metabolism have been reported.
METHODS: OPN plasma concentrations were determined in 31 morbidly obese patients (5 men, 26 women, BMI 46.2+/-7.1 kg/m2, age 41+/-11 years; mean+/-SD) before and 18 months after bariatric surgery, together with parameters of bone metabolism and inflammation.
RESULTS: OPN concentrations increased by +20.3+/-26.6 ng/ml (mean+/-SD, p<0.01), concomitant to a weight loss of -38+/-22 kg, and a decrease in BMI by -13.1+/-7.7 kg/m2 (both p<0.01). HOMA-index improved from 5.2+/-3.4 to 1.5+/-1.0 (p<0.01). Calcium concentrations slightly decreased, and phosphate increased (-0.06+/-0.13 mmol/l and +0.08+/-0.16 mmol/l, respectively; both p<0.05), while 25-OH-Vitamin D3 remained unchanged and PTH tended to increase (+5.1+/-14.0 pg/ml, p=0.054). Monocyte chemoattractant protein 1 and interleukin 18 were significantly decreased and associated with HOMA both before and after bariatric surgery. DeltaOPN was correlated with DeltaPTH, but not with other parameters.
CONCLUSIONS: OPN plasma concentrations increased concomitant to weight loss after bariatric surgery, which was independent from an improvement of insulin sensitivity and a decrease of inflammatory markers. Further studies are needed to differentiate whether these changes in bone metabolism after bariatric surgery are secondary to calcium deficiency or an adaptation to weight loss.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18452050     DOI: 10.1007/s11695-008-9532-9

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  25 in total

1.  Gastrointestinal surgery for severe obesity: National Institutes of Health Consensus Development Conference Statement.

Authors: 
Journal:  Am J Clin Nutr       Date:  1992-02       Impact factor: 7.045

Review 2.  Bariatric surgery in patients with morbid obesity and type 2 diabetes.

Authors:  Guntram Schernthaner; John M Morton
Journal:  Diabetes Care       Date:  2008-02       Impact factor: 19.112

3.  MCP-1 is induced by receptor activator of nuclear factor-{kappa}B ligand, promotes human osteoclast fusion, and rescues granulocyte macrophage colony-stimulating factor suppression of osteoclast formation.

Authors:  Michael S Kim; Christopher J Day; Nigel A Morrison
Journal:  J Biol Chem       Date:  2005-02-17       Impact factor: 5.157

Review 4.  Osteopontin: a versatile regulator of inflammation and biomineralization.

Authors:  C M Giachelli; S Steitz
Journal:  Matrix Biol       Date:  2000-12       Impact factor: 11.583

5.  Progression of diabetic nephropathy enhances the plasma osteopontin level in type 2 diabetic patients.

Authors:  Hiroshi Yamaguchi; Masahiko Igarashi; Akihiko Hirata; Hiromi Tsuchiya; Kazuhiko Sugiyama; Yoshihiro Morita; Yumi Jimbu; Hiroshi Ohnuma; Makoto Daimon; Makoto Tominaga; Takeo Kato
Journal:  Endocr J       Date:  2004-10       Impact factor: 2.349

6.  Vitamin D deficiency in obese patients and changes in circulating vitamin D metabolites following jejunoileal bypass.

Authors:  H Hey; K H Stokholm; B Lund; B Lund; O H Sørensen
Journal:  Int J Obes       Date:  1982

7.  Plasma osteopontin levels and expression in adipose tissue are increased in obesity.

Authors:  Javier Gómez-Ambrosi; Victoria Catalán; Beatriz Ramírez; Amaia Rodríguez; Inmaculada Colina; Camilo Silva; Fernando Rotellar; Carmen Mugueta; María J Gil; Javier A Cienfuegos; Javier Salvador; Gema Frühbeck
Journal:  J Clin Endocrinol Metab       Date:  2007-06-26       Impact factor: 5.958

8.  Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial.

Authors:  James A de Lemos; David A Morrow; Michael A Blazing; Petr Jarolim; Stephen D Wiviott; Marc S Sabatine; Robert M Califf; Eugene Braunwald
Journal:  J Am Coll Cardiol       Date:  2007-11-13       Impact factor: 24.094

9.  Calcium metabolism in the morbidly obese.

Authors:  Nahid Hamoui; Gary Anthone; Peter F Crookes
Journal:  Obes Surg       Date:  2004-01       Impact factor: 4.129

10.  Enhancement of osteoclastic bone resorption and suppression of osteoblastic bone formation in response to reduced mechanical stress do not occur in the absence of osteopontin.

Authors:  M Ishijima; S R Rittling; T Yamashita; K Tsuji; H Kurosawa; A Nifuji; D T Denhardt; M Noda
Journal:  J Exp Med       Date:  2001-02-05       Impact factor: 14.307

View more
  10 in total

1.  Effect of sleeve gastrectomy on osteopontin circulating levels and expression in adipose tissue and liver in rats.

Authors:  Andoni Lancha; Rafael Moncada; Víctor Valentí; Amaia Rodríguez; Victoria Catalán; Sara Becerril; Beatriz Ramírez; Leire Méndez-Giménez; Gema Frühbeck; Javier Gómez-Ambrosi
Journal:  Obes Surg       Date:  2014-10       Impact factor: 4.129

2.  A Pilot, Randomized Study in Women of Nutrition-Related Clinical Chemistry at 6 Weeks after Roux en Y Gastric Bypass: Comparison of Two Nutrition Support Plans.

Authors:  Robert A DiSilvestro; Patricia Choban; Fernando N Aguila; Marcus Miller; Elizabeth Joseph
Journal:  Obes Surg       Date:  2019-09       Impact factor: 4.129

3.  Association of osteopontin and tumor necrosis factor-α levels with insulin resistance in obese patients with obstructive sleep apnea syndrome.

Authors:  F Sarac; O K Basoglu; C Gunduz; H Bayrak; C Biray Avci; F Akcicek
Journal:  J Endocrinol Invest       Date:  2010-10-08       Impact factor: 4.256

Review 4.  Effect of Bariatric Surgery on Serum Inflammatory Factors of Obese Patients: a Systematic Review and Meta-Analysis.

Authors:  Moein Askarpour; Dana Khani; Ali Sheikhi; Ehsan Ghaedi; Shahab Alizadeh
Journal:  Obes Surg       Date:  2019-08       Impact factor: 4.129

Review 5.  Effect of Surgically Induced Weight Loss on Biomarkers of Endothelial Dysfunction: a Systematic Review and Meta-Analysis.

Authors:  Javad Seyyedi; Shahab Alizadeh
Journal:  Obes Surg       Date:  2020-09       Impact factor: 4.129

6.  Comparative effects of gastric bypass and sleeve gastrectomy on plasma osteopontin concentrations in humans.

Authors:  Andoni Lancha; Rafael Moncada; Víctor Valentí; Amaia Rodríguez; Victoria Catalán; Sara Becerril; Beatriz Ramírez; Leire Méndez-Giménez; María J Gil; Fernando Rotellar; Secundino Fernández; Javier Salvador; Gema Frühbeck; Javier Gómez-Ambrosi
Journal:  Surg Endosc       Date:  2014-03-13       Impact factor: 4.584

7.  Inflammatory markers and bariatric surgery: a meta-analysis.

Authors:  S Raghavendra Rao
Journal:  Inflamm Res       Date:  2012-05-16       Impact factor: 4.575

8.  Cardiovascular Biomarker Profiles in Obesity and Relation to Normalization of Subclinical Cardiac Dysfunction after Bariatric Surgery.

Authors:  Sanne M Snelder; Nadine Pouw; Yaar Aga; Manuel Castro Cabezas; L Ulas Biter; Felix Zijlstra; Isabella Kardys; Bas M van Dalen
Journal:  Cells       Date:  2022-01-26       Impact factor: 6.600

9.  Elevated expression of osteopontin may be related to adipose tissue macrophage accumulation and liver steatosis in morbid obesity.

Authors:  Adeline Bertola; Vanessa Deveaux; Stéphanie Bonnafous; Déborah Rousseau; Rodolphe Anty; Abdelilah Wakkach; Moncef Dahman; Joan Tordjman; Karine Clément; Siobhán E McQuaid; Keith N Frayn; Pierre-Michel Huet; Jean Gugenheim; Sophie Lotersztajn; Yannick Le Marchand-Brustel; Albert Tran; Philippe Gual
Journal:  Diabetes       Date:  2008-10-24       Impact factor: 9.461

Review 10.  Osteopontin: A novel regulator at the cross roads of inflammation, obesity and diabetes.

Authors:  Florian Kahles; Hannes M Findeisen; Dennis Bruemmer
Journal:  Mol Metab       Date:  2014-03-22       Impact factor: 7.422

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.